Analyses of clinical samples have shown that the expression of CSC markers (CD44, CD133 and ALDH1A) is low in primary tumours but is enhanced in tumours immediately after chemotherapy treatment but reduces back to their original levels at recurrence, suggesting that the initial expression of CSCs markers identifies chemoresistant cells [71]. This evidence concerns the gene PROM1 and neoplasm.